Trials
2 active
3 in total · 2 in the EU
What this is
- How it works
- CCR5 Co-receptor Antagonist FDA class
- Tested for
- Long COVID
- Main trialPhase 2/3
- “The IMPACT Long Covid Treatment clinical study (IMPACT-LC) is testing two repurposed and previously approved drugs, Maraviroc and Atorvastatin, for the treatment of non-hospitalized subjects with Long COVID. The main goals of the clinical study are to determine if this combination drug therapy can improve neurocognitive and physical functions in Long Covid patients, such as fatigue severity, heart rate, blood pressure, digestion, breathing, dizziness, and cognitive function. A secondary goal is to determine if biomarker levels, measured by a diagnostic test, can improve during treatment. To…”In the company’s words, NCT06974084 on ClinicalTrials.gov
Other drugs for Long COVID
- REGENECYTEStemCyte, Inc. · Phase 3
- ApabetaloneResverlogix Corp · Phase 2/3
- Nogapendekin alfa inbakiceptImmunityBio · Phase 2
- VYD2311Invivyd, Inc. · Phase 2
- RimonabantSinfatin S.L · Phase 2
- Paragon Novel Metabolic RegulatorParagonClinicals Inc. · Phase 2
Coming up1
- 1 DecPhase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Not yet recruiting | 1 Dec 2026 | A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID | |
| Phase 2Authorised | not given | Phase II, multicenter, open-label, randomized, controlled, open-label clinical trial to eliminate the latent reservoir of HIV-1 by administration of high doses of antiretroviral drugs. | |
| Phase 4Ended | not given | Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026